Artemisinin resistance in Cambodia: A clinical trial designed to address an emerging problem in Southeast Asia

Clinical Infectious Diseases

Volumn 51, Issue 11, 2010, Pages

  Noedl, Harald ^a   Se, Youry ^b   Sriwichai, Sabaithip ^b   Schaecher, Kurt ^b   Teja Isavadharm, Paktiya ^b   Smith, Bryan ^b   Rutvisuttinunt, Wiriya ^b   Bethell, Delia ^b   Surasri, Sittidech ^b   Fukuda, Mark M ^b   Socheat, Duong ^c   Thap, Lon Chan ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c National Center for Parasitology Entomology and Malaria Control   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ARTESUNATE; DIHYDROARTEMISININ; QUININE SULFATE; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CAMBODIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTHEAST ASIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; CAMBODIA; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PLASMA; PLASMODIUM FALCIPARUM; QUININE; RECURRENCE; TETRACYCLINE; THAILAND; TREATMENT FAILURE; YOUNG ADULT;

EID: 78649891852     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657120     Document Type: Article

References (35)

1. Noedl H. Artemisinin resistance: how can we find it? Trends Parasitol 2005; 21:404-5.
2. Noedl H, Se Y, Schaecher K, et al. N Engl J Med 2008; 359:2619-20.
3. Chotivanich K, Udomsangpetch R, McGready R, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis 2002; 185:1538-41. (Pubitemid 34507982)
4. World Health Organization (WHO). Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO/HTM/RBM/2003.50. Geneva: WHO, 2003.
5. Siriyanonda1 D, Meléndez V, Teja-Isavadharm P, et al. LC/MS analysis of artesunate and dihydroartemisinin in plasma following a single step protein precipitation (abstract 344). In: Program and abstracts of the 54th annual meeting of the American Society of Tropical Medicine and Hygiene (Washington, DC). Deerfield, IL: American Society of Tropical Medicine and Hygiene, 2005.
6. Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS. A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am J Trop Med Hyg 2004; 71:711-4.
7. Noedl H, Bronnert J, Yingyuen K, et al. Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob Agents Chemother 2005; 49:3575-7.
8. Houzé S, Munier A, Paoletti X, Kaddouri H, Ringwald P, Le Bras J. Shelf life of predosed plates containing mefloquine, artemisinin, dihydroartemisinin, and artesunate as used for in vitro Plasmodium falciparum susceptibility assessment. J Clin Microbiol 2007; 45:2734-6.
9. Ranford-Cartwright LC, Taylor J, Umasunthar T, et al. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg 1997; 91:719-24.
10. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438-47.
11. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
12. Woodrow CJ, Haynes RK, Krishna S. Artemisinins. Postgrad Med J 2005; 81:71-8.
13. Pickard AL, Wongsrichanalai C, Purfield A, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 2003; 47:2418-23.
14. Alker AP, Lim P, Sem R, et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 2007; 76:641-7.
15. Uhlemann AC, Cameron A, Eckstein-Ludwig U, et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol 2005; 12:628-9.
16. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424:957-61.
17. Jambou R, Legrand E, Niang M, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005; 366:1960-3.
18. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353:1965-7.
19. Duffy PE, Sibley CH. Are we losing artemisinin combination therapy already? Lancet 2005; 366:1908-9.
20. Gogtay NJ, Kadam VS, Karnad DR et al. Probable resistance to parenteral artemether in Plasmodium falciparum: case reports from Mumbai (Bombay), India. Ann Trop Med Parasitol 2000; 94:519-20.
21. Luxemburger C, Brockman A, Silamut K, et al. Two patients with falciparum malaria and poor in vivo responses to artesunate. Trans R Soc Trop Med Hyg 1998; 92:668-9.
22. Sahr F, Willoughby VR, Gbakima AA, Bockarie MJ. Apparent drug failure following artesunate treatment of Plasmodium falciparum malaria in Freetown, Sierra Leone: four case reports. Ann Trop Med Parasitol 2001; 95:445-9.
23. Vijaykadga S, Rojanawatsirivej C, Cholpol S, et al. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health 2006; 11:211-9.
24. Noedl H, Jongsakul K, Satimai W, et al. Artemisinin resistance along the Thai-Cambodian border [abstract 374]? In: Programs and abstracts of the 55th annual meeting of the American Society of Tropical Medicine and Hygiene (Atlanta, Georgia). Deerfield, IL: American Society of Tropical Medicine and Hygiene, 2006.
25. Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T. Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria. Southeast Asian J Trop Med Public Health 1991; 22:534-43.
26. Borrmann S, Adegnika AA, Missinou MA, et al. Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon. Antimicrob Agents Chemother 2003; 47:901-4.
27. Alin MH, Kihamia CM, Bjorkman A, et al. Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. Am J Trop Med Hyg 1995; 53:639-45.
28. Hassan AM, Ashton M, Kihamia CM, Mtey GJ, Björkman A. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg 1996; 90:61-5.
29. Schwarz NG, Oyakhirome S, Pötschke M, et al. 5-day nonobserved artesunate monotherapy for treating uncomplicated falciparum malaria in young Gabonese children. Am J Trop Med Hyg 2005; 73:705-9. (Pubitemid 41446717)
30. Looareesuwan S, Wilairatana P, Vanijanonta S, et al. Monotherapy with sodium artesunate for uncomplicated falciparum malaria in Thailand: a comparison of 5- and 7-day regimens. Acta Trop 1997; 67:197-205.
31. Price R, van Vugt M, Nosten F, et al. Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria. Am J Trop Med Hyg 1998; 59:883-8. (Pubitemid 29028916)
32. Menard D, Matsika-Claquin MD, Djalle D, et al. Association of failures of seven-day courses of artesunate in a non-immune population in Bangui, Central African Republic with decreased sensitivity of Plasmodium falciparum. Am J Trop Med Hyg 2005; 73:616-21.
33. 2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother 2006; 50:480-9.
34. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med 2009; 361:540-1.
35. Noedl H, Krudsood S, Chalermratana K, et al. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis 2006; 43:1264-71.